Existing evidence indicates that NLRP3 inflammasome activation during acute MI with enhanced IL-1 activity and increase in IL-6 and CRP levels contributes to the risk of post-infarct HF and that IL-1 targeting therapy may prevent HF development. This evidence concerns the gene IL1A and myocardial infarction.